Alan Clement and David Abramowitz spoke at the 13th Annual Paragraph IV Disputes Conference, April 29-30, 2018 in New York.
Alan spoke on "Assessing Secondary Considerations in Light of Blocking Patents Post-Acorda" and David’s topic was "New Developments in Market Access and Exclusivities."
Each spring, leading pharmaceutical patent litigators for brand name and generic drug companies gather at the Paragraph IV Disputes conference to discuss, debate, and analyze the latest trends, judicial rulings and legislative developments affecting Hatch-Waxman litigation.
As the industry prepares to address the fall out of global pharmaceutical patent losses of billions of dollars on the Hatch-Waxman landscape, the time for this conference has never been more relevant.
For additional details, click here.